Drilldown: Medicines
Medicines > fda max 
:
100 mg/d or
100 mg/day (adult); 1.4 mg/kg/day or 100 mg total (pediatric, whichever lower) or
600 mg/d
:
100 mg/d or
100 mg/day (adult); 1.4 mg/kg/day or 100 mg total (pediatric, whichever lower) or
600 mg/d Use the filters below to narrow your results.
generic:
brand:
classes:
Multimodal serotonergic; HSDD treatment (1) ·
[[:Category:ADHD medicines|ADHD medicine]] (1) ·
[[:Category:Angiotensin_receptor_blockers|Angiotensin receptor blocker (ARB)]] (1) ·
[[:Category:Antihyperglycemic_agents|Antihyperglycemic agent]] (1) ·
[[:Category:Antihypertensives|Antihypertensive]] (1) ·
[[:Category:Antitussives|Antitussive]] (1) ·
[[:Category:Beta-lactam_antibiotics|β-lactam antibiotic]] (1) ·
[[:Category:Cephalosporins|Cephalosporin (third-generation)]] (1) ·
[[:Category:DPP-4_inhibitors|DPP-4 inhibitor]] (1) ·
[[:Category:Incretin_modulators|Incretin pathway modulator]] (1) ·
[[:Category:NRIs|Selective norepinephrine reuptake inhibitor (NRI)]] (1)
mechanism:
None (2) ·
5-HT1A agonist, 5-HT2A antagonist, with weaker activity at D4 and other receptors. Net effect involves enhanced prefrontal dopaminergic/noradrenergic tone with decreased serotonergic inhibition of sexual desire. (1) ·
'"`UNIQ--vote-00000015-QINU`"' Pediatric ingestion (capsule chewed or punctured) releases the free local anesthetic and causes seizures, cardiac arrhythmia, and death'"`UNIQ--ref-00000016-QINU`"'. (1) ·
'"`UNIQ--vote-000000B6-QINU`"' Active metabolite EXP3174 is ~10-40-fold more potent than the parent and accounts for most of the antihypertensive effect; CYP2C9 polymorphism affects conversion'"`UNIQ--ref-000000B7-QINU`"'. (1) ·
'"`UNIQ--vote-00000762-QINU`"' Largely renally cleared, hence the eGFR-tiered dosing. Rare but well-documented signals: acute pancreatitis (uncertain causal contribution), severe joint pain, and bullous pemphigoid (class effect, especially in older Asian patients)'"`UNIQ--ref-00000763-QINU`"'. (1)
uses:
'"`UNIQ--vote-00000013-QINU`"' (1) ·
'"`UNIQ--vote-00000017-QINU`"' (1) ·
'"`UNIQ--vote-000000B8-QINU`"', '"`UNIQ--vote-000000B9-QINU`"', '"`UNIQ--vote-000000BA-QINU`"', '"`UNIQ--vote-000000BB-QINU`"' (1) ·
'"`UNIQ--vote-000002C1-QINU`"' (1) ·
'"`UNIQ--vote-00000764-QINU`"' (1) ·
'"`UNIQ--vote-000009DF-QINU`"', '"`UNIQ--vote-000009E0-QINU`"', '"`UNIQ--vote-000009E1-QINU`"', '"`UNIQ--vote-000009E2-QINU`"', '"`UNIQ--vote-000009E3-QINU`"' (1)
starting dose:
100 mg at bedtime daily (1) ·
100 mg PO once daily (50 mg if CrCl 30-44; 25 mg if <30 or dialysis) (1) ·
100-200 mg PO TID (max 600 mg/d) (1) ·
300 mg PO BID, or 600 mg PO once daily, ×5-10 days; pediatric 14 mg/kg/d (1) ·
50 mg PO daily (25 mg in volume depletion or hepatic impairment) (1) ·
Children ≤70 kg: 0.5 mg/kg/day, titrate to 1.2 mg/kg/day after 3 days. Adults and children >70 kg: 40 mg PO once daily for 3 days, then 80 mg/day, then if needed 100 mg/day after 2-4 weeks (1)
preparations:
fda max: (Click arrow to add another value)
routes:
onset:
15-20 minutes (1) ·
ADHD effect emerges over 1-2 weeks (slower than psychostimulants); full effect 4-6 weeks (1) ·
BP effect 1-2 weeks; antihypertensive peak 3-6 weeks (1) ·
Effects accumulate over weeks; assess at 8 weeks (1) ·
Hours (1) ·
Postprandial glucose effect within days; HbA1c by 12 weeks (1)
duration:
halflife:
2 hours (parent); 6-9 hours for active carboxylic acid metabolite EXP3174'"`UNIQ--ref-000000BC-QINU`"' (1) ·
Not well characterized'"`UNIQ--ref-00000018-QINU`"' (1) ·
~1.7 hours'"`UNIQ--ref-000009E4-QINU`"' (1) ·
~11 h (1) ·
~12.4 hours'"`UNIQ--ref-00000765-QINU`"' (1) ·
~5 hours in extensive CYP2D6 metabolizers; ~21 hours in CYP2D6 poor metabolizers'"`UNIQ--ref-00000014-QINU`"' (1)
bioavailability:
16-21% capsule, 25% suspension (oral; iron and antacids reduce absorption substantially)'"`UNIQ--ref-000009E5-QINU`"' (1) ·
Not well characterized'"`UNIQ--ref-00000019-QINU`"' (1) ·
~33% (1) ·
~33% (extensive first-pass via CYP2C9 and CYP3A4)'"`UNIQ--ref-000000BD-QINU`"' (1) ·
~63% (oral; extensive first-pass)'"`UNIQ--ref-00000015-QINU`"' (1) ·
~87% (oral)'"`UNIQ--ref-00000766-QINU`"' (1)
pregnancy:
'''Contraindicated in pregnancy''' (all trimesters); fetal renal injury, oligohydramnios, hypocalvaria, hypotension. Stop on detection'"`UNIQ--ref-000000BE-QINU`"' (1) ·
Generally considered safe in pregnancy.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited data; switch to insulin where feasible.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited human data.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited human data; animal reproductive studies not conducted<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Not indicated; pregnancy effects unknown (1)
legal:
Rx-only in US (REMS program) (1) ·
[[USLegal:Prescription only|Rx-only]] in US (4) ·
[[USLegal:Prescription only|Rx-only]] in US. '''Not a controlled substance''', the principal clinical selling point versus psychostimulant ADHD options. Carries the antidepressant-class '''Boxed Warning''' for suicidal ideation in pediatric patients'"`UNIQ--ref-00000016-QINU`"' (1)
Showing below up to 6 results in range #1 to #6.